Continuous Manufacturing, Emerging Technology and the Office of Pharmaceutical Quality

Size: px
Start display at page:

Download "Continuous Manufacturing, Emerging Technology and the Office of Pharmaceutical Quality"

Transcription

1 Continuous Manufacturing, Emerging Technology and the Office of Pharmaceutical Quality ISPE Continuous Manufacturing Conference Baltimore, MD Robert Iser, M.S. Acting Director, Office of Process & Facilities FDA/CDER/OPQ 1

2 Objectives Discuss how Emerging Technology fits within the Office of Pharmaceutical Quality Introduce OPQ s Integrated Quality Assessment Approach Share Pre-Approval Inspection Considerations for Continuous Manufacturing Sites 2

3 Pharmaceutical CGMPs for the 21st Century - A Risk-Based Approach Encourage the early adoption of new technological advances by the pharmaceutical industry Enhance the consistency and coordination of FDA's drug quality regulatory programs, in part, by further integrating enhanced quality systems approaches into the Agency s business processes and regulatory policies concerning review and inspection activities Ensure that regulatory review, compliance, and inspection policies are based on state-of-the-art pharmaceutical science 3

4 Office of Pharmaceutical Quality (OPQ) Mission The Office of Pharmaceutical Quality assures that quality medicines are available to the American public Vision The Office of Pharmaceutical Quality will be a global benchmark for regulation of pharmaceutical quality Slogan One Quality Voice 4

5 The Office of Pharmaceutical Quality A single unit in CDER dedicated to drug product quality The creation of one quality voice streamlining quality oversight throughout the lifecycle of a drug product Encourages the use of modern, more efficient manufacturing technologies Established consistent quality standards and clear expectations for industry Balances potential quality risks with the risk of a patient not getting a drug Anticipated quality problems before they develop to help prevent drug shortages Emphasizes quality metrics and surveillance techniques to help monitor quality across facilities 5

6 OPQ Immediate Office Acting Director: Mike Kopcha Deputy Director: Lawrence Yu Office of Program and Regulatory Operations Acting Director: Giuseppe Randazzo Office of Policy for Pharmaceutical Quality Acting Director: Ashley Boam Office of Biotech Products Director: Steven Kozlowski Office of New Drug Products Director: Sarah Pope Miksinski Office of Lifecycle Drug Products Director: Susan Rosencrance Office of Testing and Research Director: Cindy Buhse Office of Surveillance Acting Director: Russ Wesdyk Office of Process and Facilities Acting Director: Robert Iser

7 Emerging Technology (ET) Technology with which the FDA has limited review or inspection experience, but that has the potential to modernize the body of knowledge associated with pharmaceutical development New technology (or technology not previously applied to pharmaceutical applications) intended to support more robust, predictable, and/or cost- effective processes or novel products Innovative or novel products, manufacturing processes, or analytical technology subject to CMC review Examples of ET include: Continuous manufacturing of drug substances and drug products On-demand manufacturing of drug products Use of robots in pharmaceutical manufacturing 3-D printed tablets New container and closure systems for injectable products 7

8 FDA s Emerging Technology Program The Emerging Technology (ET) Program provides a centralized collaborative platform for FDA and industry to accelerate the development and adoption of emerging technologies 8

9 Emerging Technology Team (ETT) A small cross-functional team with representation from all relevant CDER and ORA review and inspection programs Chair: Sau (Larry) Lee, Associate Director of Science, OPQ PM: Cheryl Kaiser (OPQ/OPRO) Current Members: Thomas O Connor(OPQ/IO-SRS), Celia Cruz (OPQ/OTR), Mohan Sapru & Ray Frankewich (OPQ/ONDP), Geoffrey Wu (OPQ/OLDP), Kurt Brorson (OPQ/OBP), Grace McNally, Sharmista Chatterjee & Bryan Riley (OPQ/OPF), Tara Gooen (OPQ/OPPQ), Rebeca Rodriguez & Susanne Richardson (ORA) Other subject matter experts as needed Contact ETT: CDER-ETT@fda.hhs.gov 9

10 Emerging Technology Team Functions Serve as a centralized location for external inquiries on novel technologies Provide a forum for firms to engage in early dialogue with FDA to support innovation Ensure consistency, continuity, and predictability in review and inspection ETT member(s) plays an active or leadership role in the OPQ quality assessment team for applications containing an emerging technology Identify and evaluate roadblocks relating to existing guidance, policy, or practice Help establish quality standards and policy, as needed Facilitate knowledge transfer to relevant CDER and ORA review and inspection programs 10

11 DRAFT ET Guidance Provides recommendations to companies interested in participating in a program involving the submission of CMC information containing emerging manufacturing technology to FDA. Applicable to companies that intend the technology to be included as part of an: investigational new drug application (IND) or original or supplemental new drug application (NDA), abbreviated new drug application (ANDA), or biologic license application (BLA) reviewed by the Center for Drug Evaluation and Research (CDER), and where that technology meets other criteria described in this guidance. 11

12 CONTINUOUS MANUFACTURING 12

13 What is Continuous Manufacturing? In a continuous manufacturing process, the material(s) and product(s) are continuously charged into and discharged from the system, throughout the duration of the process. 1 13

14 Why Continuous Manufacturing? FDA recognizes that continuous manufacturing (CM) has the potential to increase the efficiency, flexibility, agility, and robustness of pharmaceutical manufacturing Integrated processing with fewer steps No manual handling, increased safety Shorter processing times Smaller equipment and facilities More flexible operation Lower capital costs, fewer work-in-progress materials Reduced environmental foot print Feasible for manufacturing small batch sizes On-line monitoring and control for increased product quality assurance in real time Amenable to Real Time Release Testing approaches 14

15 Continuous Manufacturing Emerging Technology FDA has identified CM as an emerging technology CM is still a new manufacturing approach for pharmaceutical application in comparison with other industries (e.g., food and chemicals) Adoption and advancement of system engineering tools (e.g., model-based design and optimization and advanced process control) may be needed to maximize potential benefits CM has a great deal of potential to increase the efficiency, flexibility, agility, and robustness of pharmaceutical manufacturing, and thus have a huge impact on product quality CM could provide benefits to both patients and industry 15

16 Trends in Continuous Manufacturing NDA approvals ~15 ETT & Industry meetings since the launch of ET program in early 2014 providing feedback on the development of CM processes (FYI for all ET proposals) Drug substances Drug products Small molecules and biotechnology products Facility visits 16

17 INTEGRATED QUALITY ASSESSMENT 17

18 Integrated Quality Assessment (IQA) IQA team provides an aligned, patient-focused and riskbased drug product quality recommendations for BLAs, NDAs, and ANDAs, inclusive of drug substance, drug product, manufacturing, and facilities. IQA Teams consist of: Application Technical Lead (ATL) Regulatory Business Process Manager (RBPM) Discipline Reviewers (includes OPF & ORA) Advisors - Lab (OTR), Policy (OPPQ), Surveillance (OS), etc. 18

19 ANDA IQA Team Roles Role / Task Scientific Content / Initial Risk Assessment Process and Timeline IQA Executive Summary Assessment of Drug Substance / DMF Assessment of Drug Product Assessment of the Manufacturing Process Assessment of Facilities Assessment of Biopharmaceutics Assessment of Microbiology Assessment of Environmental Analysis Labeling & Package Insert PAI Inspections Lifecycle Knowledge Management Responsible (General Case) ATL / IQA Team RBPM ATL / IQA Team DS/DP Reviewer DP Reviewer Process Reviewer Facility Reviewer Bio pharm Reviewer Micro Reviewer EA reviewer DP Reviewer ORA Lead / SMEs participate ATL/ IQA Team 19

20 Integrated Quality Assessment & PAIs The IQA aligns review and PAI functional areas A PAI is part of the overall quality assessment performed by the Integrated Quality Assessment (IQA) team IQA team members (ORA, OPF, others) share knowledge regarding the manufacturing process described in the application and any information from a pre-operational review PAI team led by ORA, includes OPF, perhaps ONDP, and ETT member. Inspection findings are fed back into IQA team Communication within the IQA team regarding the inspection findings and firm s corrective actions 20

21 Benefits of IQA Fully informed risk-based decision making related to quality Benefit to review team, as team better understands the implementation of the process and controls Benefit to inspection, as team contributes their knowledge and expertise of review process Unified voice from inspection and review functions of the IQA team Enhanced risk-based decision making related to quality 21

22 OPQ-ORA Interaction OPQ and ORA members may participate on a Pre- Operational Review/Visit (POR/POV) Interactions prior to the PAI Harmonize on critical areas of focus for the PAI Based on expertise, clear division of areas to evaluate during the PAI Interactions during the PAI PAI team members consistently apprised each other of any findings or concerns Home Team at White Oak routinely informed throughout inspection Interactions after the PAI Each PAI team member contributed to drafting the EIR (Establishment Inspection Report) & contributes to IQA assessment recommednations 22

23 Pre-Operational Reviews of Manufacturing Facilities Provides CDER and ORA an opportunity to visit the manufacturing facility prior to the pre-approval inspection. FDA can review and discuss any manufacturing facility, equipment and process issues. Valuable feedback to the manufacturer prior to review and inspection. Provides FDA the opportunity to become aware of future manufacturing operations and new technologies. Early involvement with new technology will increase efficiency and timely quality evaluation of manufacturing operations. 23

24 Will there be a PAI for my ET Application? Considerations: Expected to be significant changes to manufacturing facility, equipment, and process Novel technology for which manufacturer and FDA do not have extensive experience Presents challenges to readiness for manufacturing objective of the pre-approval inspection program Complexity and criticality of manufacturing process Aspects of automation and equipment design can be more readily assessed during inspection than review 24

25 Pre-Approval Inspection (PAI) Determination - Risk Based Approach Facility Risk: Are there manufacturing risks associated with the inspectional history and current operations at this facility that impact may application? Facility Changes. Process Risk: What are the manufacturing risks associated with the proposed unit operations in this application? Experience with this process. Product Risk: Is there limited knowledge about the manufacture of this product? What s the connection between manufacturing and clinical efficacy and patient safety? OPF Facility Reviewers assess these three risks to make the PAI Inspection recommendation Product Process Facility 25

26 Post-PAI Follow-Up Initial Recommendation on PAI by the District Office Completion of Establishment Inspection Report (EIR) Communication between District Office and OPQ regarding inspection and corrective actions Evaluation of PAI EIR and firm 483 response within OPQ to make final recommendation Feedback to application review committee regarding inspection findings Final recommendations for all facilities related to application made by OPF (as part of IQA team recommendations) Inspection information factored into lifecycle management for facility, determine need for future inspections 26

27 CM & PAIs 27

28 Inspection Considerations (1) Pharmaceutical Quality System (PQS): Are there any modifications to the existing PQS that is needed for CM? Structure of effective QA Unit should handle CM, although processes and definitions may need revisions Definition of a lot or batch Traceability for segments of the production run; for systemic quality events impacting many segments, may need a look back for previously released segments 28

29 Inspection Considerations (2) PQS (continued): Collection of conforming product When will product diversion occur? Will this be planned in advance; criteria established? Is there data to support decisions on product collection or diversion (Start; Pause; Shutdown)? Expected or Unexpected Events? Who makes the decision? 29

30 Inspection Considerations (3) PQS (continued): Process for reviewing batch records: Timelines for review (tight deadlines) Quantity of information reviewed (large quantity of electronic process information) Sequence of batch record review and product segment release Batch review after product segment complete; or simultaneous review during production? 30

31 Inspection Considerations (4) Automation of Manufacturing Processes: Level of software validation dependent upon risks Written requirements documents for functionality Appropriate level of QA involvement in development, testing, and change control Clarity on automated actions versus operator actions Adequacy of training of operators to use software Resolution of alarms; impact on product quality Proactive anticipation of events; involvement of the QA Unit 31

32 Inspection Considerations (5) Electronic Batch Records: What level of review performed for process and analytical data needed for batch release Define the information to be reviewed by QA How are atypical events and work-around situations recorded Controls in place to assure that records are Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA) 32

33 Inspection Considerations (6) Facilities and Equipment: Dedicated or Multi-Product Equipment (identification, cleaning) Single Use or Reusable Equipment (equipment durability; leachables) Detection of accumulated materials within equipment (observability) Cleaning of complex equipment; many connections; extensive tubing Equipment function over long durations (maintenance, calibration) 33

34 Inspection Considerations (7) Facilities and Equipment: Continuous operations or shut downs during operations (overnight); duration of product hold and impact on quality Bioburden levels for wet processes Equipment temperature and impact on product stability 34

35 Inspection Considerations (8) Process Validation: Design Facilities; Qualification of Equipment and Utilities Materials appropriate for intended use Verifying utility and equipment; built and installed in accordance with design specifications Verification that utility systems and equipment operate in accordance with process requirements in anticipated operating ranges Different approaches used for this stage 35

36 Final Thoughts Emerging Technology Guidance is available Innovation (including CM) is encouraged and FDA appreciates transparent communication OPQ s Integrated Quality Assessment lends itself to assessment of Emerging Technology Variety of mechanisms in place to provide feedback related to both review and inspection Inspection Considerations for ET are adapted from assessment of traditional technologies 36

37 Acknowledgements Christina Capacci-Daniel Sharmista Chatterjee Dave Doleski Arwa El Hagrasy Sau (Larry) Lee Rapti Madurawe 37

38 Thank you for your attention! Additional Questions: 38

How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry

How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry Moderator: Lawrence Yu Speakers: Thomas O Connor & Sharmista Chatterjee Emerging Technology: A Key Enabler for Modernizing

More information

How Process Models can Facilitate Quality Risk Management for Emerging Technologies

How Process Models can Facilitate Quality Risk Management for Emerging Technologies How Process Models can Facilitate Quality Risk Management for Emerging Technologies Thomas O Connor, Ph.D. FDA-AIChE Workshop on Adopting Continuous Manufacturing North Bethesda, MD March 2 th, 2016 2

More information

Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology

Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology Sau (Larry) Lee, Ph.D. Associate Director for Science Office of Pharmaceutical

More information

Office of Pharmaceutical Quality: Why, What, and How?

Office of Pharmaceutical Quality: Why, What, and How? Office of Pharmaceutical Quality: Why, What, and How? Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research NIPTE Annual Scientific Conference

More information

FDA s Evolving Approach to Pharmaceutical Quality

FDA s Evolving Approach to Pharmaceutical Quality FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.

More information

Office of Pharmaceutical Quality Key Quality Initiatives

Office of Pharmaceutical Quality Key Quality Initiatives Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research

More information

Quality by Design, Clinical Relevance & Lifecycle Considerations

Quality by Design, Clinical Relevance & Lifecycle Considerations Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives

More information

CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals

CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC

More information

Implementing Quality Systems

Implementing Quality Systems Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving

More information

Future of Pharmaceutical Quality and the Path to Get There

Future of Pharmaceutical Quality and the Path to Get There Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,

More information

Importance of ICH Guidance in Fulfilling Process Validation Requirements

Importance of ICH Guidance in Fulfilling Process Validation Requirements Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process

More information

Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003

Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003 Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared

More information

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective 14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office

More information

PDA 71 Years of Connecting People, Science and Regulation

PDA 71 Years of Connecting People, Science and Regulation PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International

More information

Q8 and Q8 annex An industry Perspective

Q8 and Q8 annex An industry Perspective Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference

More information

Value Paper. Are you PAT and QbD Ready? Get up to speed

Value Paper. Are you PAT and QbD Ready? Get up to speed Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more

More information

Claudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group

Claudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel

More information

CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.

CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment

More information

Quality Risk Management

Quality Risk Management Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.

More information

Quality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development

Quality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com

More information

Quality by Design and OINDP. Today s Presentation

Quality by Design and OINDP. Today s Presentation Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition

More information

STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN

STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications

More information

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does

More information

JUST SCRATCHING THE SERVICE

JUST SCRATCHING THE SERVICE CONTRACT MANUFACTURING, PACKAGING & NEW EQUIPMENT TECHNOLOGY FOR THE BIOPHARM/PHARMACEUTICAL INDUSTRY OFFICIAL MEDIA SPONSOR OF W W W. P H A R M P R O. C O M V O L U M E 3 0, N U M B E R 4 M AY 2 0 1 5

More information

Training. Education CALENDAR FEDEGARI TECH CENTERS DM#407036

Training. Education CALENDAR FEDEGARI TECH CENTERS DM#407036 2016 CALENDAR COLLABORATION IN THE LIFE SCIENCES WORLD Valued customer, The need to increase efficiency and reliability in pharmaceutical manufacturing presents firms with unique opportunities to develop

More information

Midwest Regional Forum. Work Smarter Not Harder Leveraging Prior Knowledge to Accelerate CMC Programs

Midwest Regional Forum. Work Smarter Not Harder Leveraging Prior Knowledge to Accelerate CMC Programs Midwest Regional Forum Work Smarter Not Harder Leveraging Prior Knowledge to Accelerate CMC Programs Tuesday, October 23, 2018 Loews Chicago O Hare Hotel Rosemont, IL Meeting Co-chairs: Sarah Demmon, Eli

More information

Pharmaceutical Manufacturing and Engineering Catalog Excerpt

Pharmaceutical Manufacturing and Engineering Catalog Excerpt Pharmaceutical Manufacturing and Engineering Catalog Excerpt PME 530 Introduction to Pharmaceutical Manufacturing Pharmaceutical manufacturing is vital to the success of the technical operations of a pharmaceutical

More information

Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems

Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems A robust and secure manufactured product is the desired end result for pharmaceutical companies. Scale-up and

More information

Connecting People, Science and Regulation

Connecting People, Science and Regulation Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway Suite 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm

More information

Challenges of Implementation of ICH Q 8

Challenges of Implementation of ICH Q 8 Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated

More information

Terrence Tougas. Dennis Sandell

Terrence Tougas. Dennis Sandell Terrence Tougas Boehringer Ingeheim, Ridgefield, CT Dennis Sandell S5 Consulting, Lund, Sweden (c) 2011 Sandell & Tougas 1 Transforming the general concept of Quality into objective, well defined and actionable

More information

peace of mind For from development to commercial supply

peace of mind For from development to commercial supply For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number

More information

PMDA perspective on Quality by Design for pharmaceutical products

PMDA perspective on Quality by Design for pharmaceutical products PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference

More information

FDA Centers of Excellence in Regulatory and Information Sciences

FDA Centers of Excellence in Regulatory and Information Sciences FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in

More information

Leader in Pharmaceutical Films

Leader in Pharmaceutical Films TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation

More information

QbD Application in Japan: PMDA Perspective

QbD Application in Japan: PMDA Perspective CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals

More information

CDRH PMA Critical to Quality (CtQ) Pilot

CDRH PMA Critical to Quality (CtQ) Pilot 1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. CDRH PMA

More information

WHO Regulatory Systems Strengthening Program

WHO Regulatory Systems Strengthening Program WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking

More information

Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team

Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team

More information

WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future. By: Hite Baker

WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future. By: Hite Baker WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future By: Hite Baker August 2017 Introduction This Facility Focus Survey Report explores how to design sterile

More information

Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel

Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel mljweitzel@msn.com Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over

More information

USP Research & Innovation Program

USP Research & Innovation Program USP Research & Innovation Program Ding Ming, Ph.D. Vice president, Research & Innovation United States Pharmacopeial Convention (USP) October 13, 2016 USP Programs and Products Impact Millions Worldwide

More information

the SPD company Dr Clive Simon, Principal, The SPD Company.

the SPD company Dr Clive Simon, Principal, The SPD Company. the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated

More information

Software as a Medical Device (SaMD)

Software as a Medical Device (SaMD) Software as a Medical Device () Working Group Status Application of Clinical Evaluation Working Group Chair: Bakul Patel Center for Devices and Radiological Health US Food and Drug Administration NWIE

More information

What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012

What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012 What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012 What We Heard Report: The Case for Change 1 Report of What We Heard: The Case for Change Consultation

More information

Master Data Management: Building readiness for regulations Compliance can benefit, but so can internal speed and efficiency

Master Data Management: Building readiness for regulations Compliance can benefit, but so can internal speed and efficiency Master Data Management: Building readiness for regulations Compliance can benefit, but so can internal speed and efficiency What s at stake? As part of their obligation to communicate accurate and changing

More information

ICH Q7 - API. Presented by Ashley Isbel 4 July, 2016

ICH Q7 - API. Presented by Ashley Isbel 4 July, 2016 ICH Q7 - API Presented by Ashley Isbel 4 July, 2016 ICH Q7 ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000) Adopted or referenced by: PIC/S in 2007 - Guide

More information

Embracing Quality by Design. Applying QbD concepts can help CMOs create value

Embracing Quality by Design. Applying QbD concepts can help CMOs create value Embracing Quality by Design Applying QbD concepts can help CMOs create value By Russ Somma, Ph.D. and Andrew A. Signore, PE, PMP-DBIA, CPIP SommaTech, LLC Integrated Project Services (IPS) THE PHARMACEUTICAL

More information

OSIsoft. Users Conference 2013

OSIsoft. Users Conference 2013 OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,

More information

The Process Analytical Technology Initiative: PAT and the Pharmacopeias

The Process Analytical Technology Initiative: PAT and the Pharmacopeias The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004

More information

API hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.

API hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy. API hapis High Potency Active Pharmaceutical Ingredients High Potency Active Pharmaceutical Ingredients Innovation made. Easy. 2 High Potency Active Pharmaceutical Ingredients High potency APIs are our

More information

Analytical Development Labs

Analytical Development Labs Analytical Development Labs S-Matrix ADL Purdue Technology Center 5225 Exploration Drive Suite S-2357 Indianapolis, IN 46241 USA URL: www.smatrix.com Overview Major Pharmaceutical companies worldwide use

More information

ICH Q8, 9 & 10 and the Impact on the QP

ICH Q8, 9 & 10 and the Impact on the QP 1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug

More information

VENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA

VENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA WORLD COMPLIANCE SEMINARS SPEAKER:- BRIAN G. NADEL President of Brian G. Nadel, GMP Consulting, LLC. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry - 2017

More information

Leveraging Med Device Expertise to Develop Combination Products

Leveraging Med Device Expertise to Develop Combination Products Leveraging Med Device Expertise to Develop Combination Products 20 th Annual Drug Delivery Partnership Conference January 20, 2016 Dirk Smith VP of Technology Solutions Minnetronix, Inc. 250 employees,

More information

Issues in Emerging Health Technologies Bulletin Process

Issues in Emerging Health Technologies Bulletin Process Issues in Emerging Health Technologies Bulletin Process Updated: April 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The

More information

Update on Lessons Learned from the EMA-FDA QbD Pilot

Update on Lessons Learned from the EMA-FDA QbD Pilot Update on Lessons Learned from the EMA-FDA QbD Pilot IFPAC 2014 Annual Meeting 22 January 2014 Sharmista Chatterjee, Ph.D. CMC Lead for QbD, ONDQA/OPS/CDER/FDA Background One of the projected outcomes

More information

DRAFT. Cardiac Safety Research Consortium CSRC. Membership Committee Charter. 12September2018. Table of Contents

DRAFT. Cardiac Safety Research Consortium CSRC. Membership Committee Charter. 12September2018. Table of Contents DRAFT Cardiac Safety Research Consortium CSRC Membership Committee Charter 12September2018 Table of Contents Purpose of the CSRC Membership Charter and CSRC Membership Committee Composition, Responsibilities

More information

A BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL

A BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL A BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL PRESENTATION OUTLINE Introduction The Improved Comparative Study

More information

PROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION

PROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol.1, No.4, pp 1339-1344, Oct-Dec 2009 PROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION Deepak D. Pokharkar*,

More information

Global GMP Harmonisation A Japanese Perspective

Global GMP Harmonisation A Japanese Perspective Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE

More information

Section heading. Strapline sub-heading

Section heading. Strapline sub-heading Section heading Strapline sub-heading Smart every time NextPharma stands out as your pharmaceutical development and manufacturing partner with fast, flexible and tailored solutions for markets worldwide

More information

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,

More information

Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series

Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding

More information

Timescales for Change A Look at Innovation in the Pharmaceutical Industry

Timescales for Change A Look at Innovation in the Pharmaceutical Industry Timescales for Change A Look at Innovation in the Pharmaceutical Industry 3rd FDA/PQRI Conference on Advancing Product Quality 23 Mar 2017 Robert F. Meyer, Ph.D. Global Pharmaceutical Commercialization

More information

FSMA Update. Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018

FSMA Update. Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018 FSMA Update Jennifer Thomas Interim Director for FSMA Operations Center for Food Safety and Applied Nutrition Food and Drug Administration May 2018 Foundational Rules Regulation Final Rule Published Preventive

More information

Symposium on Continuous Manufacturing of Pharmaceuticals Notes

Symposium on Continuous Manufacturing of Pharmaceuticals Notes 1 2012 11 13 Symposium on Continuous Manufacturing of Pharmaceuticals Notes These are notes from the first open meeting regarding Novartis- MIT Center for Continuous Manufacturing (CCM). The meeting is

More information

Training Prospectus Public Course Dates

Training Prospectus Public Course Dates Training Prospectus 2018 Public Course Dates Assuring Compliance in Life Science Operating extensively within the global pharmaceutical, biotech, medical device and related healthcare industries, the Honeyman

More information

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on

More information

Coatings technology overview

Coatings technology overview Coatings technology overview Coatings technology and the chemistry of collaboration In a competitive global coatings market, the difference between merely surviving and thriving can often lie in the efficacy

More information

Medicines Manufacturing in the UK 2017

Medicines Manufacturing in the UK 2017 Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership

More information

Centre for the Advancement of Health Innovations (CAHI)

Centre for the Advancement of Health Innovations (CAHI) Centre for the Advancement of Health Innovations (CAHI) Excellence in Clinical Innovation and Technology Evaluation Monday, April 16 th, 2012 The Old Mill Inn and Spa, Toronto ON Leslie Levin MB, MD, FRCP

More information

MAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals

MAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals MAH Responsibilities including the Management of CMOs QP Forum 2017 - Workshop Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals 25 th April 2017 Alexion Pharmaceuticals in Ireland A

More information

Artwork Lifecycle Process Management. Vilva Natarajan CEO, Karomi

Artwork Lifecycle Process Management. Vilva Natarajan CEO, Karomi Artwork Lifecycle Process Management Vilva Natarajan CEO, Karomi Which Artworks? Labels Cartons PIL Pack Inserts PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Section in the SPL Mock Artwork for Submission Commercial

More information

Feedback EMEA / Industry Discussion

Feedback EMEA / Industry Discussion Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD,

More information

This is a preview - click here to buy the full publication PUBLICLY AVAILABLE SPECIFICATION. Pre-Standard

This is a preview - click here to buy the full publication PUBLICLY AVAILABLE SPECIFICATION. Pre-Standard This is a preview - click here PUBLICLY AVAILABLE SPECIFICATION Pre-Standard IEC PAS 62435 First edition 2005-09 Electronic components Long-duration storage of electronic components Guidance for implementation

More information

Assessing the Welfare of Farm Animals

Assessing the Welfare of Farm Animals Assessing the Welfare of Farm Animals Part 1. Part 2. Review Development and Implementation of a Unified field Index (UFI) February 2013 Drewe Ferguson 1, Ian Colditz 1, Teresa Collins 2, Lindsay Matthews

More information

The Transition to Model-Based Drug Development. Phase 1: Formalizing the Pharmacometric Process

The Transition to Model-Based Drug Development. Phase 1: Formalizing the Pharmacometric Process 1780 Wehrle Drive Suite 110 Buffalo, New York 14221 716.633.3463 cognigencorp.com The Transition to Model-Based Drug Development Phase 1: Formalizing the Pharmacometric Process By Thaddeus H. Grasela,

More information

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective 1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation

More information

Requirements Gathering using Object- Oriented Models

Requirements Gathering using Object- Oriented Models Requirements Gathering using Object- Oriented Models Cycle de vie d un logiciel Software Life Cycle The "software lifecycle" refers to all stages of software development from design to disappearance. The

More information

2008 Course Programs Schedule

2008 Course Programs Schedule 2008 Course Programs Schedule Basic Laboratory Safety Laboratory Safety Biostatistics for the Non-Statistician - Basic Applied cgmps for Pharmaceutical and Allied Industries Good Clinical Practices (GCP)

More information

Progressive Licensing and the Modernization of the Canadian Regulatory Framework

Progressive Licensing and the Modernization of the Canadian Regulatory Framework Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER

More information

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ ISO 14971 Risk Management as Part of Design Control Human Factors and Usability Engineering Definitions How People

More information

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ 1) Device Discovery and Ideation 2) Medical Device Regulations 3) Product Life Cycle 4) Design Controls 5) Medical

More information

4/8/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota

4/8/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ 1) Device Discovery and Ideation 2) Medical Device Regulations 3) Product Life Cycle 4) Design Controls 5) Medical

More information

Phase 1 US Compliance Report

Phase 1 US Compliance Report Implementation of Regulatory Information Submission Standards (IRISS) ectd Tool Interoperability Group (ETIG) ectd Tool Interoperability and Compliance Study 3 (ETICS 3) ETICS 15 April 2011 Implementation

More information

November 18, 2011 MEASURES TO IMPROVE THE OPERATIONS OF THE CLIMATE INVESTMENT FUNDS

November 18, 2011 MEASURES TO IMPROVE THE OPERATIONS OF THE CLIMATE INVESTMENT FUNDS November 18, 2011 MEASURES TO IMPROVE THE OPERATIONS OF THE CLIMATE INVESTMENT FUNDS Note: At the joint meeting of the CTF and SCF Trust Fund Committees held on November 3, 2011, the meeting reviewed the

More information

YOUR INJECTION MOLDING PARTNER

YOUR INJECTION MOLDING PARTNER YOUR INJECTION MOLDING PARTNER crescentind.com 70 East High Street New Freedom, PA 17349 717.746.0663 WHO WE ARE Engineering-Driven, Technology-Based Injection Molder At Crescent Industries, our expertise

More information

Medical Device Risk Management

Medical Device Risk Management Page 1 of 14 X Medical Device Risk Management Posted 14 February 2018 By Darin OppenheimerSuraj Ramachandran This article focuses on risk management in the medical device industry and reviews organizational

More information

Towards malaria elimination: ADB-supported work at Myanmar FDA

Towards malaria elimination: ADB-supported work at Myanmar FDA Towards malaria elimination: ADB-supported work at Myanmar FDA Valerio Reggi 25 January 2018 Disclaimer: The views expressed in this paper/presentation are the views of the author and do not necessarily

More information

ASEPTIC PROCESSING, TODAY AND FUTURE

ASEPTIC PROCESSING, TODAY AND FUTURE ASEPTIC PROCESSING, TODAY AND FUTURE Dublin, Ireland, 4 October 2018 Marco Delgado Rueda ALL RIGHTS RESERVED 2018 PAREXEL INTERNATIONAL CORP. AGENDA Today s Reality and Needs Issues and Probable Causes

More information

WHITE PAPER FACILITY FOCUS: GMP Facility Modernization. By: David M. Marks, P.E.

WHITE PAPER FACILITY FOCUS: GMP Facility Modernization. By: David M. Marks, P.E. WHITE PAPER FACILITY FOCUS: GMP Facility Modernization By: David M. Marks, P.E. July 2017 Introduction In recent years, intensified industry competition and cost pressures have renewed interest in modernizing

More information

IGDRP Mission, Scope, How it works

IGDRP Mission, Scope, How it works IGDRP Mission, Scope, How it works IGDRP-EDQM Workshop Strasbourg, France 13 May 2016 Dr. Craig Simon Associate Director, Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada

More information

CDER SBIA Generic Drugs Forum 2019 Presenter and Facilitator Biographies

CDER SBIA Generic Drugs Forum 2019 Presenter and Facilitator Biographies Presenter and Facilitator Biographies Om Anand, PhD Division of Biopharmaceutics Office of New Drug Products (ONDP) Office of Pharmaceutical Quality (OPQ) Center for Drug Evaluation and Research (CDER)

More information

Digital Medical Device Innovation: A Prescription for Business and IT Success

Digital Medical Device Innovation: A Prescription for Business and IT Success 10 September 2018 Digital Medical Device Innovation: A Prescription for Business and IT Success A Digital Transformation is reshaping healthcare. New technology, mobility, and advancements in computing

More information

ALL RAW MATERIALS ARE NOT CREATED EQUAL.

ALL RAW MATERIALS ARE NOT CREATED EQUAL. ALL RAW MATERIALS ARE NOT CREATED EQUAL. Meet Diagnostics Elite DIAGNOSTIC SOLUTIONS Reimagine what s possible. REDUCE RISK. INCREASE CONSISTENCY. The Diagnostics Elite program is more than just a set

More information

Thank you for the opportunity to comment on the Audit Review and Compliance Branch s (ARC) recent changes to its auditing procedures.

Thank you for the opportunity to comment on the Audit Review and Compliance Branch s (ARC) recent changes to its auditing procedures. Jim Riva, Chief Audit Review and Compliance Branch Agricultural Marketing Service United States Department of Agriculture 100 Riverside Parkway, Suite 135 Fredericksburg, VA 22406 Comments sent to: ARCBranch@ams.usda.gov

More information

Training Prospectus Public Course Dates

Training Prospectus Public Course Dates Training Prospectus 2019 Public Course Dates Honeyman Group Assuring Compliance in Life Science Operating extensively within the global pharmaceutical, biotech, medical device and related healthcare industries,

More information

International Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT

International Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT Research Article Analytical Chemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY SARAVANA KUMAR.V

More information